|
Research Area
|
|
Description
|
Cancer |
|
Biological Activity
|
|
Description
|
Tipifarnib (Zarnestra, R115777) is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM. |
|
Targets
|
FTase |
|
|
|
|
|
|
IC50 |
0.6 nM [1] |
|
|
|
|
|
|
In Vitro
|
Using Tipifarnib 5 μM for 72 hours, the percentage of apoptotic cells is significantly higher in drug-treated compared to DMSO-treated LGL T-cells. Using T-cells from healthy donors, Tipifarnib reduces the percentage of IFNγ-positive cells in a time-dependent manner. Tipifarnib reduces the amount of activated Ras in precipitates compared to DMSO. [2] Tipifarnib exerts selective in vitro toxicity against clonal MDS hematopoiesis at concentrations less than 10 nM the effect being more prominent in white cell progenitors. This action is not due to apoptosis induction as both normal and MDS progenitors displays equivalent DiOC3 and annexin V expression up to 72 hours after exposure to Tipifarnib. [3] Combining Tipifarnib with 10 nM 4-OH-tamoxifen in the presence of E2 reduces the IC50 8-fold from 400 to 50 nM. [4] Tipifarnib induces apoptosis in U937 cells. [5] In addition, Tipifarnib inhibits isolated human farnesyltransferase for a lamin B peptide and for the K-RasB peptide with IC50 of 0.86 nM and 7.9 nM, respectively. [6] |
|
In Vivo
|
Ki-67 is lower in the tumors treated with E2 withdrawal plus R115777 compared with E2 withdrawal alone. The combination of tamoxifen and R115777 results in significantly lower Ki-67 compared with either tamoxifen or R115777 alone (mean of 5% versus 16.9% and 67.3%, respectively). [4] In contrast, no significant difference in apoptotic scores is seen between the treatment groups. R115777 alone also reduces the CTI compared with control. The combination of tamoxifen and R115777 or R115777 coupled with E2 withdrawal is most effective at lowering the CTI (0.8 and 0.7, respectively), which may account for the decrease in tumor volume. [4] |
|
Clinical Trials
|
Tipifarnib is currently in phase II clinical trials in previously untreated older adults with AML and baseline presence of a specific 2-gene expression signature ratio. |
|
Features
|
Tipifarnib is a potent and selective farnesyl protein transferase inhibitor with significant antitumor effects. |
|
Protocol
|
|
Cell Assay
[4]
|
| Cell Lines |
MACS-selected CD34+ cells |
| Concentrations |
2.5 nM, 10 nM, 25 nM and 50 nM |
| Incubation Time |
48 hours |
| Methods |
MACS-selected CD34+ cells are seeded in Methocult 4435 ‘complete’ 1% bovine serum albumin, 3 U/mL recombinant human (rh) erythropoietin, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine and the following cytokines: 50 ng/mL rh stem cell factor, 20 ng/mL rh GM-CSF, 20 ng/mL rh IL-3, 20 ng/mL rh IL-6 and 20 ng/mL h G-CSF. DMSO or Tipifarnib is added at the concentrations of 2.5, 10, 25 and 50 nM at day 1. All cultures are performed in duplicates and the numbers of colonies are scored after 14 days of incubation at 37 °C in a humidified incubator containing 5% CO2. |
|
Animal Study
[4]
|
| Animal Models |
Female ovariectomized Ncr foxhead nude mice |
| Formulation |
20% w/v β-cyclodextrin (pH 2.5) |
| Doses |
50 mg/kg |
| Administration |
Oral gavage |
|
References |
|
[1] Margolin KA, et al. Clin Cancer Res. 2012, 18(4), 1129-1137.
|
|
[2] Bai F, et al. Cancer Immunol Immunother. 2012, 61(4), 523-533.
|
|
[3] Kotsianidis I, et al. Acta Haematol. 2008, 120(1), 51-56.
|
|
[4] Martin LA, et al. Mol Cancer Ther. 2007, 6(9), 2458-2467.
|
|
[5] Krzykowska-Petitjean K, et al. J Cancer Res Clin Oncol. 2012, 138(3), 537-544.
|
|
[6] End DW, et al. Cancer Res. 2001, 61(1), 131-137.
|
|